KRAS and pancreatic neoplasm: The results showed that TCR-001–transduced allogeneic T cells, but not mock T cells, specifically killed human pancreatic cancer organoid PDAC-59 and PAC-229, but not PC-2, PC-34, and PC-104, all of which express the natural KRAS G12V mutation and HLA-A*11:01, suggesting that while these 3 organoids can be recognized by the TCR-engineered T cells (Figure 5, B–D), the recognition is not sufficient to induce cytolysis (Figure 6, A and B, and Supplemental Figure 8).